ライフサイエンスコーパス: congestive

1 A congestive and friable mucosa was seen, and the resectio

2 ally enable assessment of necroinflammatory, congestive, and fibrotic processes of chronic liver dise

3 Only congestive cardiac failure (CCF) was an independent pred

4 ne [1%]), bone pain (one [1%] vs four [2%]), congestive cardiac failure (four [2%] vs two [1%]), myoc

5 tion (OR 8.74, 95% CI 5.27 to 14.77), having congestive cardiac failure (OR 1.72, 95% CI 1.18 to 2.50

6 o [2%]), atrial fibrillation (two [2%]), and congestive cardiac failure (two [2%]).

7 ion group (sepsis [n=2], septic shock [n=1], congestive cardiac failure [n=1], and unknown cause [n=1

8 noma, and one hypertensive heart disease and congestive cardiac failure in the bictegravir group and

9 When she faced heart decompensation, this congestive condition led to an acute liver injury overla

10 ardiorespiratory end points, such as asthma, congestive heart disease, and lung cancer.

11 0-day death or combined endpoint (defined as congestive heart failure >/= New York Heart Association

12 of grade 3 neuropathy, and 2 had symptomatic congestive heart failure (0.5%; 95% CI, 0.1 to 1.8), bot

13 ; HR: 1.18; 95% CI: 1.04 to 1.34; p = 0.01), congestive heart failure (107 events; HR: 1.25; 95% CI:

14 ), coronary artery disease (34% versus 32%), congestive heart failure (19% versus 15%), and diabetes

15 lized for acute myocardial infarction (19%), congestive heart failure (25%), pneumonia (30%), and con

16 04), stroke (2.43% vs. 1.93%; p = 0.05), and congestive heart failure (3.75% vs. 2.25%; p < 0.0001) t

17 7.4 years; P = .035) and more likely to have congestive heart failure (35.3% vs 24.5%; P < .001) and

18 ents, and the most common cause of death was congestive heart failure (37%).

19 -20.4%), cardiac dysrhythmias (21.7%-29.0%), congestive heart failure (40.7%-56.1%), acute (5.9%-20.1

20 r dysfunction, but blacks had more prevalent congestive heart failure (43% versus 34%; P=0.04) and le

21 ry disease (26.6 to 12.6% of admissions) and congestive heart failure (8.5 to 5.4% of admissions).

22 OR: 0.36; 95% CI: 0.31 to 0.42; p < 0.001), congestive heart failure (adjusted OR: 0.82; 95% CI: 0.7

23 le gender (aOR, 1.61; 95% CI, 1.42 to 1.84), congestive heart failure (aOR, 1.20; 95% CI, 1.03 to 1.3

24 % confidence interval [CI]: 157.7 to 238.0), congestive heart failure (aOR: 49.1; 95% CI: 37.4 to 64.

25 adjusted odds ratio [aOR]: 4.06; p < 0.001), congestive heart failure (CHF) (aOR: 2.20; p = 0.011) an

26 e to UFPs and nitrogen dioxide with incident congestive heart failure (CHF) and acute myocardial infa

27 associated with greater risk of adjudicated congestive heart failure (CHF) and atherosclerotic event

28 Patients with congestive heart failure (CHF) have impaired functional

29 Congestive heart failure (CHF) is a leading cause of mor

30 uch as acute myocardial infarction (AMI) and congestive heart failure (CHF) is inconclusive, especial

31 Patients with advanced congestive heart failure (CHF) or chronic kidney disease

32 Patients with advanced congestive heart failure (CHF) or chronic kidney disease

33 valence of mental stress-induced ischemia in congestive heart failure (CHF) patients is unknown.

34 HIV-infected individuals have excess congestive heart failure (CHF) risk compared with uninfe

35 -myocardial infarction use of beta-blockers; congestive heart failure (CHF) with use of angiotensin-c

36 Cardiac death, severe congestive heart failure (CHF), and confirmed significan

37 termine hazard ratios (HR) for incident CHD, congestive heart failure (CHF), and other causes of deat

38 admissions for ischemic heart disease (IHD), congestive heart failure (CHF), and overall CVD were obt

39 In congestive heart failure (CHF), carotid body (CB) chemor

40 echolamine stimulation during development of congestive heart failure (CHF), chronic activation of Gs

41 ulation-level influenza rates in adults with congestive heart failure (CHF), coronary artery disease

42 ital arrhythmias, eclampsia or preeclampsia, congestive heart failure (CHF), length of stay, preterm

43 m from cardiology, neurology and psychiatry: Congestive Heart Failure (CHF), Major Depression Disorde

44 patients without cirrhosis and patients with congestive heart failure (CHF), matched for age, sex, an

45 rate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease

46 tions for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and whether

47 tions for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and whether

48 hospitalization or emergency room visit for congestive heart failure (CHF), outpatient diagnosis of

49 on (MI), other ischemic heart disease (IHD), congestive heart failure (CHF), stroke, chronic kidney d

50 lation (AF), myocardial infarction (MI), and congestive heart failure (CHF).

51 ions (PVCs) are a modifiable risk factor for congestive heart failure (CHF).

52 ation), Kussmaul sign, has been described in congestive heart failure (CHF).

53 n-ischemic cardiomyopathy without history of congestive heart failure (CHF).

54 ork learning of chest radiograph features in congestive heart failure (CHF).

55 uracy for chest radiography in patients with congestive heart failure (CHF).

56 astolic dysfunction without the diagnosis of congestive heart failure (HF) and with normal systolic f

57 event the rare, but serious, complication of congestive heart failure (HF) associated with anthracycl

58 litus (HR, 1.42; 95% CI, 1.01-2.00; P=0.04), congestive heart failure (HR, 1.88; 95% CI, 1.12-3.16; P

59 6; 95% confidence interval [CI], 1.80-3.11), congestive heart failure (HR, 2.16; 95% CI, 1.70-2.72),

60 Two hundred and four (6.9%) patients had new congestive heart failure (incidence, 38.42/1000 patient-

61 Here, in the International Congestive Heart Failure (INTER-CHF) study, we aimed to

62 was a composite of death, re-infarction, and congestive heart failure (major adverse cardiac events [

63 tient with a history of atrial fibrillation, congestive heart failure (NYHA II/III), stable coronary

64 sease (odds ratio, 1.22; 95% CI, 1.11-1.34), congestive heart failure (odds ratio, 1.14; 95% CI, 1.08

65 tion (OR 1.97; 95% CI 1.64-2.35; p < 0.001), congestive heart failure (OR 1.42; 95% CI 1.21-1.67; p <

66 llation (OR, 0.82; CI, 0.70-0.95; P = 0.01), congestive heart failure (OR, 0.73; CI, 0.60-0.88; P < 0

67 22; 95% CI, 1.00-1.48; P = .045), history of congestive heart failure (OR, 1.25; 95% CI, 1.12-1.39; P

68 liver disease (OR, 1.57; 95% CI, 1.39-1.77); congestive heart failure (OR, 1.49; 95% CI, 1.38-1.61);

69 Congestive heart failure (OR, 1.7; 95% CI, 1.3-2.2), car

70 (P </= 0.04), heart attack (P </= 0.01), and congestive heart failure (P </= 0.02), but not with stro

71 P<0.001), pulmonary hypertension (P<0.0001), congestive heart failure (P=0.0008), and liver disease (

72 One new serious adverse event suggestive of congestive heart failure (pertuzumab group) and one new

73 gnosis at index AKI hospitalization included congestive heart failure (primary diagnosis), decompensa

74 t disease (RR, 4.31; 95% CI, 3.38-5.49), and congestive heart failure (RR, 2.05; 95% CI, 1.29-3.25).

75 Evaluate Challenging Responses to Therapy in Congestive Heart Failure (SECRET of CHF) trials.

76 6-3.69), high-risk surgery 2.70 (2.46-2.96), congestive heart failure 2.65 (2.29-3.06), cerebrovascul

77 (age >65 [aOR 3.0, 95%CI 1.7-5.5, p<0.001], congestive heart failure [aOR 3.2, 95%CI 1.4-7.0, p=0.00

78 Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [TACTICS-HF]; NCT01644331).

79 A composite outcome of death and congestive heart failure admission was recorded.

80 et the composite end point (48 deaths and 19 congestive heart failure admissions, 2.5% 30-day deaths)

81 s were more likely to have had AKI, multiple congestive heart failure admissions, and other hospitali

82 revention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarcti

83 were to identify correlates of mortality and congestive heart failure after aortic valve replacement

84 relates of the composite outcome of death or congestive heart failure after AVR.

85 rate of major adverse cardiac events and new congestive heart failure after ST-segment-elevation myoc

86 to the emergency department with symptoms of congestive heart failure and a 1-week history of chest p

87 Dilated cardiomyopathy is a leading cause of congestive heart failure and a debilitating complication

88 radation of cardiac control in patients with congestive heart failure and a more degradation in criti

89 ing hospitalization for sepsis compared with congestive heart failure and acute myocardial infarction

90 readmissions following sepsis compared with congestive heart failure and acute myocardial infarction

91 ative to other high-risk conditions, such as congestive heart failure and acute myocardial infarction

92 on diagnoses at the time of readmission were congestive heart failure and arrhythmia.

93 high rates of readmission, predominantly for congestive heart failure and arrhythmia.

94 of left ventricular failure in patients with congestive heart failure and bronchoconstriction.

95 left ventricular (LV) decline, resulting in congestive heart failure and death.

96 g dialysis patients, warfarin users had more congestive heart failure and diabetes mellitus, but fewe

97 also compared for patients with a history of congestive heart failure and for patients aged >/=80.

98 requent; however, exacerbation of asthma and congestive heart failure and one fatal cerebral hemorrha

99 admitted to our hospital with decompensated congestive heart failure and pericardial effusion diagno

100 t Failure Score, ESCAPE [Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

101 portions of the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

102 and (2) patients in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

103 In phase 3, 19 patients with congestive heart failure and pulmonary hypertension cons

104 ase 2, 32 participants (including those with congestive heart failure and pulmonary hypertension) use

105 ment of the pathophysiology of congestion in congestive heart failure and the methods by which we det

106 re likely to have had a primary diagnosis of congestive heart failure at the time of index admission,

107 pitalized for acute myocardial infarction or congestive heart failure but not among those hospitalize

108 f acute myocardial infarction cases, 1.7% of congestive heart failure cases, and 5.8% of stroke cases

109 One patient with congestive heart failure died from refractory left ventr

110 A total of 30% to 40% of patients with congestive heart failure eligible for cardiac resynchron

111 = 4; 13.8%), unstable angina (n = 8; 27.6%), congestive heart failure exacerbations (n = 4; 13.8%), e

112 Multivariate analysis showed that congestive heart failure greater than or equal to New Yo

113 crease in abundance of Proteobacteria in the congestive heart failure group (p = 0.014), particularly

114 The top hospital quartile of ICU use for congestive heart failure had a sensitivity of 50-60% and

115 sympathetic overstimulation in patients with congestive heart failure have a negative inotropic effec

116 We conclude that dogs with congestive heart failure have dysbiosis, and we show add

117 About one-half of the patients with congestive heart failure have preserved left ventricular

118 We hypothesised that dogs with congestive heart failure have quantifiable dysbiosis com

119 earts and paroxysmal AF, although those with congestive heart failure have the greatest potential ben

120 .05-1.44), thromboembolism 1.32 (1.17-1.49), congestive heart failure HR 1.57 (1.39-1.78), depression

121 ession of, for instance, sleep disorders and congestive heart failure in diabetic patients.

122 riven by a significantly reduced rate of new congestive heart failure in the RIC and PostC group (2.7

123 of chronic obstructive pulmonary disease or congestive heart failure in univariate analyses.

124 ting as asymptomatic cardiac dysfunction and congestive heart failure in up to 57% and 16% of patient

125 Congestive heart failure is a major cause of morbidity,

126 Congestive heart failure is characterized by suppressed

127 Congestive heart failure is one of the leading causes of

128 relatively early stages, the abrupt onset of congestive heart failure is uncommon and should raise su

129 In this population, congestive heart failure is well recognised as a progres

130 l in which weight, severe liver disease, and congestive heart failure most affected fentanyl concentr

131 cardiac end point was defined as symptomatic congestive heart failure of New York Heart Association c

132 Conclusion Features of congestive heart failure on chest radiographs learned by

133 ction, stroke, gastrointestinal bleeding, or congestive heart failure or a Diagnosis Related Group cl

134 ac death or arrest, ventricular arrhythmias, congestive heart failure or arrhythmias requiring admiss

135 thin the categories of sudden death, cancer, congestive heart failure or chronic lung disease, and fr

136 in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.

137 ization was more pronounced in patients with congestive heart failure or ischemic heart disease than

138 Among high-risk subjects, those with congestive heart failure or ischemic stroke as their ind

139 nts with AA were older, presented with acute congestive heart failure or non-ST-segment-elevation myo

140 Patients with congestive heart failure or reduced left ventricular eje

141 e in the previous 6 months or who had severe congestive heart failure or severe renal impairment were

142 reast cancer, except for those with clinical congestive heart failure or significantly compromised le

143 rmed HCM presented with rapid development of congestive heart failure over 6 months, in sharp contras

144 ese steps using a hypothetical example for a congestive heart failure postdischarge clinic.

145 History of congestive heart failure predicted midodrine continuatio

146 ard Medical therapy in Elderly patients with Congestive Heart Failure randomized 499 patients with HF

147 er the inclusion of an SES measure in 30-day congestive heart failure readmission models changed hosp

148 nute walk test (6MWT) independently predicts congestive heart failure severity, death, and heart fail

149 Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure Study (TACTICS) and Study to Ev

150 A multivariable model-including angina, congestive heart failure symptoms, shockable arrest rhyt

151 cy department visits for asthma/wheezing and congestive heart failure than PM2.5.

152 ior stroke, hypertension, renal disease, and congestive heart failure than white men but lower rates

153 eing completely asymptomatic; to features of congestive heart failure to vaginal bleeding which may a

154 Congestive heart failure typically arises from cardiac m

155 visits with 17alpha(H),21beta(H)-hopane and congestive heart failure visits with elemental carbon.

156 tio, 11.42 [95% CI, 10.93-11.93]; P < .001); congestive heart failure was a negative correlatefold (o

157 t wave days, but risk of hospitalization for congestive heart failure was lower (P < .05).

158 0.48-1.35; P=0.41), and the reduction of new congestive heart failure was not statistically significa

159 ting of cardiac death, reinfarction, and new congestive heart failure were assessed during long-term

160 schemic attack, prior systemic embolism, and congestive heart failure were associated with more frequ

161 articipants, but not seniors, and those with congestive heart failure were less likely to achieve a 2

162 rdial infarction, stroke, and progression to congestive heart failure were recorded.

163 ICA trial (Atrial Fibrillation Management in Congestive Heart Failure With Ablation) did not reveal a

164 on, target vessel revascularization, and new congestive heart failure within 6 months.

165 Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure) study was conducted to address

166 of 50 dogs (15 healthy dogs and 35 dogs with congestive heart failure) were prospectively recruited,

167 med angina, silent MI, revascularization, or congestive heart failure).

168 resistance and severe cardiotoxicity (e.g., congestive heart failure).

169 adverse events (grade 2 fatigue and grade 4 congestive heart failure).

170 potension, bradycardia, bronchospasm, and/or congestive heart failure).

171 n particular, SGLT2 inhibitors lower risk of congestive heart failure, a major cardiovascular complic

172 ascular events, and disease-specific events: congestive heart failure, acute myocardial infarction, a

173 disease, ascites, sepsis, smoking, steroid, congestive heart failure, acute renal failure, and dyspn

174 ncidence of coronary artery disease, stroke, congestive heart failure, all-cause mortality, and cardi

175 s ago, are used to treat hypertension and/or congestive heart failure, although there are therapeutic

176 vent (heart attack, stroke, new or worsening congestive heart failure, amputation for ischemic gangre

177 nfarction, nonfatal stroke, new or worsening congestive heart failure, amputation for ischemic gangre

178 0 million/yr for sepsis, $229 million/yr for congestive heart failure, and $142 million/yr for acute

179 22.9%; interquartile range, 19.2-26.6%) for congestive heart failure, and 3.6% to 40.8% (median, 17.

180 tes were 20.4%, 23.6%, and 17.7% for sepsis, congestive heart failure, and acute myocardial infarctio

181 outcomes were myocardial infarction, stroke, congestive heart failure, and cardiovascular mortality.

182 ey role in the pathogenesis of hypertension, congestive heart failure, and chronic kidney disease.

183 osterone synthase) can lead to hypertension, congestive heart failure, and diabetic nephropathy.

184 Older age, congestive heart failure, and greater left ventricular d

185 age, sex, race, diabetes status, presence of congestive heart failure, and hemoglobin, serum albumin,

186 l history included diabetes mellitus type 2, congestive heart failure, and hypertension.

187 FDCM and IDCM but for both groups older age, congestive heart failure, and increased left ventricular

188 ng age, male gender, pulmonary hypertension, congestive heart failure, and liver disease are risk fac

189 Procedural complications, congestive heart failure, and low hospital AF ablation v

190 composite primary end point of death, shock, congestive heart failure, and reinfarction when compared

191 increased risk for death, cardiac death, and congestive heart failure, and subjects presenting PTF >/

192 strongly influenced by severe liver disease, congestive heart failure, and weight, factors that shoul

193 er secondary events including hip fractures, congestive heart failure, angina, falls, depression, cho

194 The primary composite was all-cause death, congestive heart failure, cardiogenic shock, and recurre

195 he in-hospital composite end point of death, congestive heart failure, cardiogenic shock, and reinfar

196 older and were more likely to have comorbid congestive heart failure, cardiomyopathy, cerebrovascula

197 percent of clopidogrel-treated patients with congestive heart failure, cholecystectomy, and lower per

198 scular disease, peripheral vascular disease, congestive heart failure, chronic obstructive pulmonary

199 has grown to include chronic kidney disease, congestive heart failure, chronic pulmonary diseases, an

200 ary outcomes were hospitalization because of congestive heart failure, coronary heart disease, new on

201 um concentrations, as occur in patients with congestive heart failure, could activate the PKD1/HDAC5/

202 ardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke

203 rior stroke, older age, atrial fibrillation, congestive heart failure, diabetes mellitus, myocardial

204 cute coronary syndrome, atrial fibrillation, congestive heart failure, DM 2, and smoking.

205 atal myocardial infarction, unstable angina, congestive heart failure, emergency coronary revasculari

206 erent comorbidities (diabetes, hypertension, congestive heart failure, hemodialysis-dependence, cance

207 .1 +/- 8.1 years, the mean CHA(2)DS(2)-VASc (congestive heart failure, hypertension, 65 years of age

208 o clinical risk factors and the CHA2DS2VASc (congestive heart failure, hypertension, 75 years of age

209 Clinical schemas, such as the CHA2DS2-VASc (congestive heart failure, hypertension, age >/= 75 years

210 Median CHADS2 score (congestive heart failure, hypertension, age >/= 75 years

211 CHA2DS2VASc scores (congestive heart failure, hypertension, age >/=75 years

212 The CHA2DS2-VASc score (congestive heart failure, hypertension, age >/=75 years

213 er PVI in association with the CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years

214 After adjustment for the CHA2DS2-VASc score (congestive heart failure, hypertension, age >/=75 years

215 African-American ethnicity to CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,

216 oint on the stroke risk scheme CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,

217 sk patients, i.e., with 0 or 1 CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,

218 ith atrial fibrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >/=75 years,

219 nd bleeding risks were assessed by using the congestive heart failure, hypertension, age >/=75 years,

220 sk factors, as measured by the CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75, diabe

221 h atrial fibrillation (AF) with a "low-risk" congestive heart failure, hypertension, age >/=75, diabe

222 erformance of ATRIA to that of CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75, diabe

223 Patients with NVAF who had a CHADS2 (congestive heart failure, hypertension, age >75 years, d

224 y mass index (BMI); and have a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >= 75 years,

225 antly older and had higher CHA(2)DS(2)-VASc (congestive heart failure, hypertension, age >=75 years,

226 in CHA2DS2-VASc score (a risk score based on congestive heart failure, hypertension, age 75 years or

227 Although the CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or

228 e in subjects with ESVEA and a CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or

229 s had atrial fibrillation, CHA(2)DS(2)-VASc (Congestive heart failure, Hypertension, Age 75 years, Di

230 average age of 70+/-12 years, a mean CHADS2 (congestive heart failure, hypertension, age>75, diabetes

231 with severe cardiovascular diseases such as congestive heart failure, hypertension, and myocardial f

232 Among AF patients, age >/=75 years, congestive heart failure, hypertension, diabetes mellitu

233 risk factors (diabetes mellitus, history of congestive heart failure, hypertension, or age older tha

234 ted in clinical studies for the treatment of congestive heart failure, hypertension, or diabetic neph

235 patients with cardiovascular disease such as congestive heart failure, ischemic heart disease, valvul

236 he primary safety endpoint were age, anemia, congestive heart failure, multivessel disease, number of

237 ac respiratory failure, atrial fibrillation, congestive heart failure, myocardial infarction, and reo

238 Patients with preexisting diabetes mellitus, congestive heart failure, or chronic or acute renal fail

239 infarction, acute coronary syndrome, stroke, congestive heart failure, or CVD death), and (ii) seriou

240 y revascularisation, hospital admission with congestive heart failure, or stroke, which was assessed

241 ent CVD manifestations such as heart attack, congestive heart failure, or stroke.

242 Congestive heart failure, paraplegia, dyspnea at rest, a

243 contained 10 categorical variables including congestive heart failure, paraplegia, reoperation, dyspn

244 05 and 2011 for acute myocardial infarction, congestive heart failure, pneumonia, or conditions requi

245 dial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficienc

246 y mass index, noncardiac surgery, history of congestive heart failure, renal disease, existing airway

247 de prostate and breast cancers, uncontrolled congestive heart failure, severe lower-urinary-tract sym

248 us thromboembolism, coronary artery disease, congestive heart failure, sleep-disordered breathing, ga

249 -salt diet, a model for hypertension-induced congestive heart failure, spermidine feeding reduced sys

250 llowed them for 2 years to assess mortality, congestive heart failure, stroke or transient ischemic a

251 s also been linked to myocardial infarction, congestive heart failure, stroke, and diabetes mellitus

252 al infarction, coronary heart disease death, congestive heart failure, stroke, incident angina, or in

253 A composite of CVD events defined as congestive heart failure, stroke, or myocardial infarcti

254 ical diagnoses (acute myocardial infarction, congestive heart failure, stroke, pneumonia, and chronic

255 kg and no history of severe liver disease or congestive heart failure, the final model, which perform

256 Among patients with congestive heart failure, the rate of occurrence of adve

257 For patients with a history of congestive heart failure, the respective rates were 22.8

258 o 2016 for SAVR, TAVR, and disease symptoms (congestive heart failure, unstable angina, non-ST-elevat

259 ospitalisation for valve-related symptoms or congestive heart failure, valve-related dysfunction requ

260 s, including hypertension, cardiac fibrosis, congestive heart failure, ventricular remodeling, and di

261 risk score PANWARDS (platelets, albumin, no congestive heart failure, warfarin, age, race, diastolic

262 were male; 13% had had a stroke; and 45% had congestive heart failure.

263 Captopril, which is generally used to treat congestive heart failure.

264 ute myocardial infarction and for those with congestive heart failure.

265 nary artery disease, arrhythmias, stroke, or congestive heart failure.

266 prevention of DOX-induced cardiotoxicity and congestive heart failure.

267 ent with pacemaker syndrome, and 1 developed congestive heart failure.

268 ass index, ejection fraction, and history of congestive heart failure.

269 ation are at an increased risk of developing congestive heart failure.

270 tant tool for the diagnosis and treatment of congestive heart failure.

271 chexia is a life threatening complication in congestive heart failure.

272 icrobial diversity and richness in dogs with congestive heart failure.

273 ated to the chronic conditions of asthma and congestive heart failure.

274 ilure was noted for patients with underlying congestive heart failure.

275 lications, such as myocardial infarction and congestive heart failure.

276 seases, such as ventricular fibrillation and congestive heart failure.

277 prematurity, sleep disordered breathing and congestive heart failure.

278 s required in 23 patients, mainly because of congestive heart failure.

279 al fibrillation, ischemic heart diseases, or congestive heart failure.

280 e consisting of death, reinfarction, and new congestive heart failure.

281 -eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein

282 ted with CKD in individual CHA(2)DS(2)-VASc (Congestive heart failure; Hypertension; Age >/=75 years;

283 ard Medical Therapy in Elderly Patients With Congestive Heart Failure; n=431), and HF-ACTION trial (H

284 mprove Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437).

285 and systemic right ventricles have premature congestive heart failure; there is also a growing concer

286 o prespecified cardiac events or symptomatic congestive heart failures were reported.

287 ontan circulation lead to the development of congestive hepatopathy and other life-threatening compli

288 We developed a murine experimental model of congestive hepatopathy through partial ligation of the i

289 These studies mechanistically link congestive hepatopathy to hepatic fibrosis.

290 Chronic passive hepatic congestion (congestive hepatopathy) leads to hepatic fibrosis; howev

291 patic inferior vena cava (pIVCL) to simulate congestive hepatopathy-induced portal hypertension in mi

292 n mice after pIVCL as well as in humans with congestive hepatopathy.

293 rget for treatment with beta3 AR agonists in congestive HF.

294 formations (AVMs) can lead to development of congestive myelopathy (Foix-Alajouanine syndrome).

295 cute to chronic neurological symptoms due to congestive myelopathy caused by intradural spinal AVMs.

296 ese findings suggest that eplerenone reduces congestive signs and symptoms, which enables clinicians

297 Right ventricular dysfunction and congestive states may contribute to alterations of renal

298 the clinicians' clinical judgement about the congestive status of the patient.

299 The development of enlarged, congestive submucosal veins could play a role in these l

300 d the resection specimen showed enlarged and congestive submucosal veins in both patients.